JP2016510766A - １型糖尿病の処置及び／又は予防のための方法及び組成物 - Google Patents

１型糖尿病の処置及び／又は予防のための方法及び組成物 Download PDF

Info

Publication number
JP2016510766A
JP2016510766A JP2015561751A JP2015561751A JP2016510766A JP 2016510766 A JP2016510766 A JP 2016510766A JP 2015561751 A JP2015561751 A JP 2015561751A JP 2015561751 A JP2015561751 A JP 2015561751A JP 2016510766 A JP2016510766 A JP 2016510766A
Authority
JP
Japan
Prior art keywords
cells
antigen
cell
progenitor cells
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015561751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510766A5 (cg-RX-API-DMAC10.html
Inventor
ザグホウアニ ハビブ
ザグホウアニ ハビブ
Original Assignee
ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ
ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ, ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ filed Critical ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ
Publication of JP2016510766A publication Critical patent/JP2016510766A/ja
Publication of JP2016510766A5 publication Critical patent/JP2016510766A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015561751A 2013-03-08 2014-03-10 １型糖尿病の処置及び／又は予防のための方法及び組成物 Pending JP2016510766A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775115P 2013-03-08 2013-03-08
US61/775,115 2013-03-08
PCT/US2014/022321 WO2014138725A1 (en) 2013-03-08 2014-03-10 Methods and compositions for the treatment and/or prevention of type 1 diabetes

Publications (2)

Publication Number Publication Date
JP2016510766A true JP2016510766A (ja) 2016-04-11
JP2016510766A5 JP2016510766A5 (cg-RX-API-DMAC10.html) 2017-04-06

Family

ID=51492039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561751A Pending JP2016510766A (ja) 2013-03-08 2014-03-10 １型糖尿病の処置及び／又は予防のための方法及び組成物

Country Status (7)

Country Link
US (2) US11338036B2 (cg-RX-API-DMAC10.html)
EP (1) EP2964750B1 (cg-RX-API-DMAC10.html)
JP (1) JP2016510766A (cg-RX-API-DMAC10.html)
CN (1) CN105358678A (cg-RX-API-DMAC10.html)
AU (1) AU2014225307A1 (cg-RX-API-DMAC10.html)
CA (1) CA2904586A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014138725A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2018057825A1 (en) * 2016-09-23 2018-03-29 The Curators Of The University Of Missouri Antigen-specific immune modulation
JP2018141728A (ja) * 2017-02-28 2018-09-13 トヨタ自動車株式会社 生活習慣病の診断方法
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
EP3873601A4 (en) * 2019-05-14 2022-03-23 Provention Bio, Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126374A1 (en) * 2002-04-09 2004-07-01 The Curators Of The University Of Missouri Sustained treatment of type 1 diabetes after expression of predisposition markers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4481946A (en) 1980-08-14 1984-11-13 Altshuler John H Bone marrow transplant method and apparatus
US4486188A (en) 1980-08-14 1984-12-04 Applied Medical Devices, Inc. Bone marrow transplant method and apparatus
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US7744876B2 (en) * 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603471B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
EP1668119A2 (en) * 2003-09-15 2006-06-14 Ramot at Tel Aviv University Ltd. Insulin-producing bone marrow derived cells and methods of generating and using same
JP4838724B2 (ja) * 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
US20120058105A1 (en) * 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126374A1 (en) * 2002-04-09 2004-07-01 The Curators Of The University Of Missouri Sustained treatment of type 1 diabetes after expression of predisposition markers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEM, vol. 205, no. 1, JPN6017044394, 2008, pages 207 - 218, ISSN: 0003829655 *
PNAS, vol. 104, no. 7, JPN6017044389, 2007, pages 2337 - 2342, ISSN: 0003829654 *

Also Published As

Publication number Publication date
CA2904586A1 (en) 2014-09-12
EP2964750A1 (en) 2016-01-13
US20220008535A1 (en) 2022-01-13
WO2014138725A1 (en) 2014-09-12
EP2964750A4 (en) 2016-08-17
US11338036B2 (en) 2022-05-24
AU2014225307A1 (en) 2015-09-24
US20160015811A1 (en) 2016-01-21
CN105358678A (zh) 2016-02-24
EP2964750B1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
JP7561893B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ－２の使用
US20220008535A1 (en) Methods and compositions for the treatment and/or prevention of type 1 diabetes
JP6416855B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
AU2014337385B2 (en) Chimeric antigen receptor T cell switches and uses thereof
KR20160014584A (ko) 염증 치료용 면역-변형된 입자
US11446314B2 (en) Immunoablative therapies
US11865168B2 (en) Compositions and methods for treating bacterial infections
US9821035B2 (en) Preparation for preventing or treating type I diabetes
US20240226168A1 (en) Engineered nk cells and uses thereof
EP3632446B1 (en) Immunoablative therapies
WO2024092108A2 (en) Pd-1+cd38hicd8+ t cells and uses thereof
EP4284434A1 (en) Methods of treating chronic active antibody-mediated rejection using btk inhibitors
US12508285B2 (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
HK40074225A (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法
EA043659B1 (ru) Иммуноаблативные виды терапии
US20160361414A1 (en) Methods of Treating and Preventing Minor Histocompatibility Antigen-Mismatched Grafts

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151007

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180703